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Abstract
A change in our current approach toward drug development is required to improve the likelihood of finding effective
treatment for patients with amyotrophic lateral sclerosis (ALS). The aim of the Treatment Research Initiative to Cure
ALS (TRICALS) is to extend the collective effort with industry and consolidate drug development paths. TRICALS has
begun a series of meetings on how to best move the field forward collaboratively, thereby addressing five major topics in
ALS clinical trials: (1) preclinical research, (2) biomarker development, (3) eligibility criteria, (4) efficacy endpoints and
(5) innovative trial design. There is an appetite for ongoing discussions of these major topics in clinical trials between
representatives from academia, patient advocacy groups, industry partners and funding bodies. Industry is open to fun-
damentally change drug development for ALS and shorten the time to effective therapy for patients by implementing
promising innovations in biomarker development, trial design, and patient selection. There is however, a pressing need
from all stakeholders for regulatory discussions and amendments of current guidelines to successfully adopt innovation
in future clinical development lines.
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Introduction
It has been nearly 25 years since the European
Medicines Agency (EMA) and the Food and Drug
Administration (FDA) approved riluzole (1).
Recently, edaravone was approved by the FDA for
delaying motor function deteroriation (2). A bene-
fit to life expectancy remains, however, to be
determined and riluzole remains the only available
treatment for European patients with amyotrophic
lateral sclerosis (ALS). Over 70 compounds have
been tested (3), but despite considerable efforts
from industry and academia, and promising early
signals, none of the treatments has been effective
in slowing the course of the illness or prolonging
survival. The reasons for this failure in translation
from animal models to human trials are multifac-
torial, but can be grouped into five major catego-
ries—namely: (1) disease heterogeneity and our
relatively limited knowledge of the interplay
between different disease mechanisms in humans;
(2) inappropriate use of pre-clinical experimental
models of mechanisms and not disease; (3) an
absence of biomarkers of pathogenic mechanisms,
markers of disease onset, and quantitative markers
of progression; (4) pharmacological challenges of
dosing and measures of target engagement and (5)
inefficient or poorly designed clinical trials (4–6).
There is now an urgent need to rethink the
clinical development pathway for ALS treatments.
This will require large-scale collaboration between
various stakeholders and important adjustments to
our current approaches. Hence, we established the
Treatment Research Initiative to Cure ALS
(TRICALS) to (1) unify academia, patient advo-
cacy groups, industry partners and funding bodies
toward a common goal in finding a cure for
patients, (2) provide a harmonized, international
infrastructure for the conduct of clinical trials and
(3) coordinate research efforts that maximize the
likelihood of successful drug development.
Currently, the TRICALS consortium consists
of 40 specialized centers in 14 countries, diagnos-
ing over 3800 patients with ALS each year.
TRICALS has begun a series of meetings with
industry partners to discuss how best to move the
field forward collaboratively, such that the best
drugs are fast-tracked to the clinic using new and
appropriately designed strategies that are both sci-
entifically robust and compliant with the require-
ments of regulatory authorities. Five main topics
are currently being explored within this collabora-
tive effort and are discussed below.
Preclinical and translational research
Background
Prior to clinical use, safety and target engagement
of new therapeutics need to be established in
experimental models. Despite its well-documented
drawbacks, the superoxide dismutase 1 (SOD1)
transgenic model remains the gold standard to
obtain preclinical insights into disease-modifying
properties. Although preclinical studies with SOD1
models can in part replicate mutant SOD1 familial
ALS, the pathophysiologic processes do not seem
to recapitulate the mechanisms underlying spor-
adic disease and animals are often treated prior to
disease onset (4,7). In addition, even if a clear
pathway is being examined, either in familial or
sporadic ALS, there is often a lack of translational
markers of target engagement. As a result, preclin-
ical studies may falsely trigger the continuation of
drugs to clinical phases.
Considerations
Optimizing preclinical study design may signifi-
cantly improve the utility and predictive value of
SOD1 and other disease models for subsequent
clinical trials (8). Moreover, given the rise of anti-
sense oligonucleotide therapies (9), specific pre-
clinical models based on a genetic mutation are
likely to prove useful to evaluate preliminary drug
safety profiles and pharmacodynamics (7,10).
Moreover, if there is a clear pathophysiological
pathway, the SOD1 model may still serve as feas-
ible preclinical model as long as adequate bio-
markers of target engagement are being
incorporated (10). It is, therefore, important to
develop not only new preclinical models, but also
to simultaneously advance biomarkers of target
engagement. Intermediate translational steps will
be required to validate and replicate these new
markers of target engagement in both preclinical as
clinical studies. Examples include the use of
neurophysiological biomarkers in phase 1 studies
(11) or misfolded SOD1 protein levels.
Future directions
There is an acknowledged need for (1) additional
models that better capture the heterogeneity of the
disease and (2) markers of target engagement to
improve preclinical to clinical translation. In vivo
preclinical models can generate valuable insight in
blood-brain-barrier permeability and, especially for
small molecules, it will be critical that the relevant
pharmacokinetic studies are included.
Furthermore, human derived stem cell models
hold promise in the determination of disease
mechanisms, opening the possibility for high-
throughput screening tools and personalized medi-
cine (12).
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Biomarkers
Background
Biomarkers can enhance patient selection, improve
prognostication, evaluate and predict biological
treatment response or serve as surrogate outcome
(4,13,14). Notwithstanding, the majority of clinical
trials may not optimally use biomarkers, thereby
potentially missing responding subgroups, lacking
the ability to quantify target engagement or subtle
treatment effects, and not gain knownledge on bio-
markers of the disease (4,14).
Considerations
The multicentre setting of clinical trials provide an
ideal environment to evaluate the association
between a biomarker and classical clinical end-
points, and to determine its reliability, test-retest
validity and site variability (15). Biomarkers should
be defined as to their potential utility in all phases
of clinical development (e.g. markers of specific
pathogenic processes; markers of specific sub-
groups; markers of target engagement; markers of
disease progression etc) (4,5). Examples of
markers that are “clinical trial ready” include neu-
rofilaments. Neurofilaments have been shown to
be stable over time and may be helpful to stratify
patients and quantify treatment response (16,17).
Other easily accessible biomarkers such as creatin-
ine, inflammatory markers or urinary P75ECD are
of potential utility and could be considered as
exploratory or secondary endpoints (14,16,18).
Future directions
Neurofilaments have the potential to improve mul-
tiple aspects of ALS clinical trials and should be
implemented at all stages of drug development.
Other markers that could be of utility include bio-
chemical, transcriptomic and proteomic measures,
neuroimaging (including PET) and advanced
neurophysiology including neuroelectric signal ana-
lysis. Combinations of different biomarkers are
likely to provide additional benefit and should
therefore be part of any clinical development pro-
gram. Open-access initiatives and prospective data
collection are vital for their validation. Ultimately,
associating treatment responses on biomarkers
with those on classical clinical endpoints could
prove their surrogate value and thereby improve
trial efficiency (19). It is thereby essential that the
same biomarkers are used in all clinical trials to
evaluate their surrogate value across a range of dif-
ferent treatment effects (20).
Eligibility criteria
Background
Eligibility criteria are the primary tool to manage
population heterogeneity and increase the prob-
ability of detecting effective compounds.
Classically defined eligibility criteria (e.g. fixed
boundaries for symptom duration, vital capacity or
diagnostic delay) are inefficient and of limited
value (21,22). Inefficiencies can be attributed to
the mathematical processes that are used to
exclude cohorts of patients whose pattern of pro-
gression is either too fast or too slow. A univariate,
step-wise application is inconsistent with the pat-
tern of human disease, which is best defined by a
multivariate combination of several characteristics
(23). Using classical eligibility criteria, large num-
bers of patients are excluded while conferring min-
imal gains in population homogeneity and severely
limiting the generalizability of results.
Considerations
Current eligibility criteria should, therefore, be
revised. This would have the dual benefits of
increasing eligibility rates and improving popula-
tion homogeneity. Simple multivariate prediction
rules could be defined for individual patients that
optimize the use of prognostic information and
improve patient selection (22). Such an approach
would bypass the need for group-level univariate
selection rules. Indeed, several validated prediction
rules are already available for different primary
outcomes (e.g. the ENCALS and Origent model
for survival and functional outcomes, respect-
ively) (23,24).
Future directions
Prediction of unfavorable disease patterns is of
particular interest for industry in order to increase
trial efficiency. However, prediction-based eligibil-
ity criteria are currently not part of trial guidelines
and regulatory discussions are required for success-
ful implementation in future settings.
Efficacy endpoints and follow-up duration
Background
Efficacy endpoints must be clinically meaningful,
sensitive to change and reliable in test-retest set-
tings (5,25). Composite survival endpoints and the
revised ALS Functional Rating Scale (ALSFRS-R)
are currently the primary measures of efficacy in
ALS clinical trials (26). Nevertheless, up to now,
early phase 2 trial outcomes that are based on the
slope of the ALSFRS-R have translated poorly to
confirmatory trials evaluating mortality (13).
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Considerations
In order to improve the translational power of
exploratory to confirmatory trials, the follow-up
duration of exploratory trials should be increased
to at least 6 months and indicate a response in
biomarkers of target engagement, or in multiple
clinical endpoints, prior to initiation of a confirma-
tory trial. As showing a therapeutic benefit on
mortality is required by European regulators for
market authorization (25), the follow-up duration
of confirmatory trials should be increased to at
least 12 months in order to design trials with feas-
ible sample sizes (27). Halting or slowing motor
neuron degeneration may be slow, and take time
to manifest in trial endpoints. The power to quan-
tify a survival benefit can be improved by employ-
ing the Joint Modeling Framework (14). In
addition, remote digital technology can help to fur-
ther define the real-world functional benefits of a
therapeutic intervention (13,27,28), whereas
extensive training on outcome measures as organ-
ized by TRICALS and Northeast ALS
Consortium (NEALS) may warrant quality control
and minimize endpoint variability (5,15).
Future directions
There is an urgent need to better translate explora-
tory clinical trials to confirmatory settings, which
requires innovation of the current clinical end-
points. The ALSFRS-R has significant limitations;
while it is unlikely in the short term that this scale
will be replaced, the differences in slope across
subscores of the ALSFRS-R should be acknowl-
edged. Trials should be adequately powered such
that the subscales of the ALSFRS-R can be ana-
lyzed individually (29). Moreover, as the
ALSFRS-R does not include a cognitive domain,
scales that assess cognition and behavioral aspects
should also be incorporated into future trials (30),
together with measures of quality of life. Clinical
staging algorithms such as King’s staging or
MiToS staging, or neurophysiological testing, may
help to identify responding subgroups and, ultim-
ately, optimize the selection of compounds for
confirmatory clinical trials (31,32). Given the dif-
ferences between EMA and FDA guidelines, add-
itional regulatory discussions may be warranted to
align clinical trials across continents.
Innovative trial design
Background
The process of designing and initiating new clinical
trials in ALS is a lengthy one. Currently, as new
biotechnology companies enter the field, new trials
are often designed from first principles rather that
utilizing a previously established protocol. This
leads to an unnecessary loss of resources and prior
knowledge, and results in wide variability in key
design characteristics such as endpoints, study dur-
ation and sample size. These arbitrary design set-
tings are likely to miss crucial treatment clues and
further delay the development of effective treat-
ment (33). Efficient, evidence-based trial method-
ology that harmonizes future clinical development
paths is urgently required, using agreed master
protocols with design input from academic
researchers, industry and patient representation.
Considerations
Multi-arm, multi-stage (MAMS) and platform
designs allow investigators to evaluate multiple
treatments simultaneously. These study designs act
as an overarching umbrella for multiple, individual
sub-studies and harmonize efficacy outcomes, visit-
ing schemes, procedures and infrastructures. This
harmonization allows for large reductions in cost,
duration, sample size and eliminates the need for
repeated startup delays and protocol development
when new compounds are discovered (34).
Future directions
The design of a master protocol requires extensive
planning, multicentre collaboration and adapta-
tions in trial methodology. Although we recognize
that elements will need to be thoroughly discussed
a priori (e.g. sharing of placebo arms and data-
sharing) (35), these initiatives can significantly
improve trial efficiency and may be of particular
interest for smaller biotech companies as they pro-
vide low-cost access to existing infrastructures and
patient populations.
The need for regulatory reform
Industry is open to fundamentally change drug
development for ALS but requires amendments of
the current regulatory guidelines to successfully
implement innovation in their pipeline. Major
future directions and regulatory themes are:
1. Relaxing the obligation of preclinical evidence
using the SOD1 mouse model, recognizing it is
a model of mechanism, not disease, and
promoting alternative human-derived models
2. Requiring the use of target-engagement
biomarkers to improve preclinical-to-clinical
translation
3. Implementing neurofilament testing in all
stages of clinical development
4. Mediating the use of ALSFRS-R subscales,
cognition, staging, advanced electrophysiology
and digital health technology to enhance the
detection of early efficacy
5. Training on outcome measures to ensure high
quality data and minimize endpoint variability
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6. Optimizing the adoption and implementation
of prediction models in the design and analysis
of clinical trials
7. Promoting the use of harmonized, innovative
and adaptive clinical trial design to
maximize efficiency
8. Advocating the adoption of unified electronic
patient records and digital biomarker collection
Conclusion
There is an appetite for ongoing discussions of
major topics in clinical trials between representa-
tives from academia, patient advocacy groups,
industry partners and fundraisers to consolidate
our current approach toward drug development for
ALS. Addressing these key topics will require fur-
ther dynamic discussions with all stakeholders, and
the EMA and FDA. Ultimately, real-world imple-
mentation in a large-scale collaboration such as
TRICALS could significantly accelerate innovation
in drug development for ALS and create a highway
toward a cure.
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